Nagai, Minami
Moriyama, Miyu http://orcid.org/0000-0003-0310-9047
Ishii, Chiharu
Mori, Hirotake http://orcid.org/0000-0002-7988-5758
Watanabe, Hikaru
Nakahara, Taku
Yamada, Takuji http://orcid.org/0000-0002-9622-1849
Ishikawa, Dai
Ishikawa, Takamasa
Hirayama, Akiyoshi http://orcid.org/0000-0002-0440-6820
Kimura, Ikuo http://orcid.org/0000-0001-8778-145X
Nagahara, Akihito
Naito, Toshio
Fukuda, Shinji http://orcid.org/0000-0001-5161-9880
Ichinohe, Takeshi http://orcid.org/0000-0002-6376-2841
Article History
Received: 14 July 2022
Accepted: 20 June 2023
First Online: 30 June 2023
Competing interests
: T.N., T.Y., D.I., and S.F. are founders and T.N. and D.I. are board members of Metagen Therapeutics, Inc., a company involved in the microbiome-based medical and drug discovery. T.Y. and S.F. are founders and board members of Metagen, Inc., a microbiome-based healthcare company. The other authors declare no competing interests.